NEW YORK: For Jessica Lescault there is no question that her six-year old English bulldog"Moose" deserves cutting-edge biotechnology cancer treatment as much as any human patient.
In recent years, the cost of genetic testing and biotech drug production has fallen sharply, making biotechnology for pets financially viable at much lower prices, industry experts said. Produced from cloned genetically engineered hamster cells over at least eight bio-processing steps, the monoclonal antibody is no less complex than comparable therapeutic proteins used in human medicine. But the cost to consumers is far less.
The cost of a highly effective new anti-itch biotech drug to treat severe atopic dermatitis in humans can run about US$30,000 a year."Cytopoint was a turning point that has made it clear that can be successful in this space," London said."Now there are an estimated five to ten companies developing antibodies for the veterinary market.
Zoetis can repurpose and optimize existing procedures, mechanisms of action and technologies, it said. "Over the last few years, the veterinary market has seen an incredibly dynamic development," said Adivo co-founder Kathrin Ladetzki-Baehs.In early August, Lescault discovered a mass on Moose's throat, soon followed by deteriorating health and a diagnosis of canine B-cell lymphoma. Moose was given one to two months to live without treatment or about a year with 25 weeks of punishing chemotherapy.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooSG - 🏆 3. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »